The relationship between HRD score based on GSS algorithm and clinicopathological characteristics,genomic mutations and prognosis in patients with high-risk and metastatic hormone-sensitive prostate cancer
The relationship between HRD score based on GSS algorithm and clinicopathological characteristics,genomic mutations and prognosis in patients with high-risk and metastatic hormone-sensitive prostate cancer
Objective To statistically analyze the relationship between homologous recombination repair deficiency(HRD)score and clinicopathological characteristics,genomic mutations in patients with high-risk and metastatic hormone-sensitive prostate cancer(mHSPC)and the prognostic predictive value in mHSPC.Methods A total of 127 patients diagnosed with high-risk prostate cancer and mHSPC,treated at the Department of Urology of Chinese PLA General Hospital during Dec.2021 and Nov.2023 were enrolled.Homologous recombination repair(HRR)gene sequencing was performed,and the genomic scar score(GSS)algorithm were conducted to calculate the HRD score.The relationship between HRD scores and clinicopathological features,genomic alterations,and prognosis were analyzed.Results The median HRD score was 1.6(0.8,5.2),30(23.6％)patients'HRD scores ≥10,and 11(8.7％)patients'HRD scores ≥20.Clinicopathological features,including ISUP classification ≥4(P=0.044)and metastatic status(P=0.008)were associated with high HRD score.Patients with mutations in the BRCA,TP53 and MYC systems had significantly higher HRD score than those with wild-type genes(P＜0.05).In mHSPC,the risk of biochemical recurrence was 12.836 times higher in patients with HRD score ≥20 than in those with＜20[OR:12.836(1.332-124.623),P=0.028].Conclusion Baseline HRD score was lower in patients with high-risk prostate cancer and mHSPC.Patients with high HRD score may have higher histological grading(ISUP≥4)and later clinical stage.Further investigation is needed to determine the threshold of HRD scores as biochemical markers suggestive of a poor prognosis.
维普
万方数据